Challenges in designing and running smouldering myeloma interventional clinical trials

Challenges in designing and running smouldering myeloma interventional clinical trials

Bibliographic Details
Main Authors:	Catherine Lecat, Eileen M Boyle, Daniel Hughes, Lydia Lee, Dean Smith, Ceri Bygrave, Karthik Ramasamy, Kwee Yong
Format:	Article
Language:	English
Published:	Wiley 2024-04-01
Series:	eJHaem
Subjects:	clinical trial multiple myeloma precursor disease smouldering myeloma
Online Access:	https://doi.org/10.1002/jha2.880

Similar Items

FDG-PET/CT, a Promising Exam for Detecting High-Risk Myeloma Patients?
by: Anne-Victoire Michaud-Robert, et al.
Published: (2020-05-01)

Daratumumab, bortezomib, and dexamethasone in relapsed or refractory multiple myeloma: subgroup analysis of CASTOR based on cytogenetic risk
by: Katja Weisel, et al.
Published: (2020-08-01)

Modeling and analytical simulation of a smouldering carbonaceous rod
by: A.A. Mohammed, et al.
Published: (2017-11-01)

A Report of a Symptomatic Progressive Myeloma during Pregnancy and Postpartum Period from Asymptomatic State
by: Gehad Elgabry, et al.
Published: (2023-05-01)

Myeloma /
by: 455001 Tanner, Jerome E., et al.
Published: (2008)

Defining Unmet Need Following Lenalidomide Refractoriness: Real-World Evidence of Outcomes in Patients With Multiple Myeloma
by: Catherine S. Y. Lecat, et al.
Published: (2021-07-01)

Anaplastic morphology in IgD multiple myeloma
by: Verónica Roldán Galiacho, et al.
Published: (2023-10-01)

Presenting Symptoms in Newly Diagnosed Myeloma, Relation to Organ Damage, and Implications for Symptom-Directed Screening: A Secondary Analysis from the Tackling Early Morbidity and Mortality in Myeloma (TEAMM) Trial
by: Stella Bowcock, et al.
Published: (2023-06-01)

Chromosomal aberrations in multiple myeloma: A study on Indian population
by: Angel Beula P. Royal, et al.
Published: (2018-01-01)

High IKZF1/3 protein expression is a favorable prognostic factor for survival of relapsed/refractory multiple myeloma patients treated with lenalidomide
by: Maryam Pourabdollah, et al.
Published: (2016-11-01)

Response and progression-free survival according to planned treatment duration in patients with relapsed multiple myeloma treated with carfilzomib, lenalidomide, and dexamethasone (KRd) versus lenalidomide and dexamethasone (Rd) in the phase III ASPIRE study
by: Meletios Dimopoulos, et al.
Published: (2018-04-01)

Daratumumab‐based induction and autologous transplantation in concomitant multiple myeloma and chronic myeloid leukemia
by: Carmine Liberatore, et al.
Published: (2023-11-01)

DIFFUSE REFLECTION ELECTRON SPECTROSCOPY IN STUDY OF BLOOD SERUM WITH MULTIPLE MYELOMA
by: Liudmila V. Plotnikova, et al.
Published: (2020-04-01)

Multiple Myeloma: An Update
by: Khalil Al-Farsi
Published: (2013-01-01)

MANDİBULADA MULTİPL MYELOMA İKİ OLGU SUNUMU
by: Hümeyra Kocaelli
Published: (2005-05-01)

Multiple myeloma and kidney disease
by: Natalia Zarankiewicz, et al.
Published: (2022-08-01)

Up-front fludarabine impairs stem cell harvest in multiple myeloma: report from an interim analysis of the NMSG 13/03 randomized placebo controlled phase II trial
by: Hans E. Johnsen, et al.
Published: (2009-08-01)

Immunoglobulin D Multiple Myeloma Presenting as Spontaneous Fracture
by: Samer Al Hadidi, et al.
Published: (2017-03-01)

Autologous hematopoietic stem cell transplantation for multiple myeloma in the age of CAR T cell therapy
by: Charlotte F. M. Hughes, et al.
Published: (2024-03-01)

Genetic Abnormalities in Extramedullary Multiple Myeloma
by: Roisin McAvera, et al.
Published: (2023-07-01)

Editorial: Molecular Mechanisms of Multiple Myeloma
by: Alessandro Gozzetti, et al.
Published: (2022-03-01)

Game of Bones: How Myeloma Manipulates Its Microenvironment
by: Tyler Moser-Katz, et al.
Published: (2021-02-01)

Risk Assessment for Newly Diagnosed Fit Young Patients with Multiple Myeloma in the Era of Novel Treatment Modalities: Should There Be Additional Factors Taken into Consideration??
by: Kaloyannidis P, et al.
Published: (2022-10-01)

CART-Cell Therapy: Recent Advances and New Evidence in Multiple Myeloma
by: Massimo Martino, et al.
Published: (2021-05-01)

Differential Diagnosis and Therapeutic Advances in Multiple Myeloma: A Review Article
by: Hussain M, et al.
Published: (2023-09-01)

Pseudohypercalcemia in Multiple Myeloma: A Case Report
by: Farzaneh Ashrafi, et al.
Published: (2016-07-01)

How we manage smoldering multiple myeloma
by: Alessandra Romano, et al.
Published: (2020-09-01)

Daratumumab for the Management of Newly Diagnosed and Relapsed/Refractory Multiple Myeloma: Current and Emerging Treatments
by: Massimo Offidani, et al.
Published: (2021-02-01)

Uterine Extramedullary Plasmacytoma as a Primary Manifestation of Multiple Myeloma
by: Ana Codorniz, et al.
Published: (2017-09-01)

Pomalidomide in the treatment of multiple myeloma: design, development and place in therapy
by: Rios-Tamayo R, et al.
Published: (2017-08-01)

MMRFVariant: Prioritizing variants in Multiple Myeloma
by: Marzia Settino, et al.
Published: (2023-01-01)

Thalidomide: near complete regression of extramedullary bulk in refractory multiple myeloma
by: A Anagnostara, et al.
Published: (2001-03-01)

Evaluating Daratumumab in the Treatment of Multiple Myeloma: Safety, Efficacy and Place in Therapy
by: Dima D, et al.
Published: (2020-08-01)

Complications of Autologous Stem Cell Transplantation in Multiple Myeloma: Results from the CALM Study
by: Anna Waszczuk-Gajda, et al.
Published: (2022-06-01)

A Tangle of Genomic Aberrations Drives Multiple Myeloma and Correlates with Clinical Aggressiveness of the Disease: A Comprehensive Review from a Biological Perspective to Clinical Trial Results
by: Mariarosaria Sessa, et al.
Published: (2020-12-01)

Effectiveness of bortezomib and bortezomib-containing programs FOR the treatment of recurrent and resistant multiple myeloma
by: T A Mitina, et al.
Published: (2010-07-01)

Testing Mayo Clinic’s New 20/20/20 Risk Model in Another Cohort of Smoldering Myeloma Patients: A Retrospective Study
by: Camille Tessier, et al.
Published: (2021-05-01)

A Rare Presentation of Biclonal Gammopathy in Multiple Myeloma with Simultaneous Extramedullary Involvement: A Case Report
by: Pragnan Kancharla, et al.
Published: (2019-07-01)

Bone Marrow Mesenchymal Stromal Cells in Multiple Myeloma: Their Role as Active Contributors to Myeloma Progression
by: Patricia Maiso, et al.
Published: (2021-05-01)

Lymphoplasmacytic variant of multiple myeloma
by: Silje Johansen, et al.
Published: (2022-05-01)